TAR-200 is named as a drug or biological intervention in 4 clinical trials in our USA, UK, China and India trial registers, none of which are currently recruiting. The lead sponsor is Janssen Research & Development, LLC. Registered phases: Phase 3 and Phase 2. Conditions studied include Urinary Bladder Neoplasms; Non-Muscle Invasive Bladder Neoplasms; Bladder Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Urinary Bladder Neoplasms | 2 |
| Non-Muscle Invasive Bladder Neoplasms | 1 |
| Bladder Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Janssen Research & Development, LLC | 4 |
| Register | TAR-200 trials |
|---|---|
| Clinical trials in USA | 4 |
| Clinical trials in UK | 3 |
| Clinical trials in China | 3 |
| Clinical trials in India | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how TAR-200 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists TAR-200 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.